Amgen Files Patent Infringement Lawsuit Against South Korean Firm Over Biosimilar Bone Drugs

The pharmaceutical giant Amgen Inc. is challenging a South Korean competitor’s plan to market biosimilar versions of its popular bone drugs, Prolia and Xgeva. In a recent filing with a New Jersey federal court, Amgen alleges that the proposed biosimilars would violate 34 of its patents. This legal dispute highlights the ongoing tensions in the pharmaceutical industry, particularly over the introduction of biosimilar drugs designed to compete with established, branded medications. For more details, visit the article by Carla Baranauckas on Law360.